Accounting for future costs in medical cost-effectiveness analysis

被引:318
|
作者
Meltzer, D [1 ]
机构
[1] NATL BUR ECON RES,CHICAGO,IL 60637
关键词
cost-effectiveness analysis; utility maximization; welfare economics; cost-benefit analysis; health care costs;
D O I
10.1016/S0167-6296(96)00507-3
中图分类号
F [经济];
学科分类号
02 ;
摘要
Most medical cost-effectiveness analyses include future costs only for related illnesses, but this approach is controversial. This paper demonstrates that cost-effectiveness analysis is consistent with lifetime utility maximization only if it includes all future medical and non-medical expenditures. Estimates of the magnitude of these future costs suggest that they may substantially alter both the absolute and relative cost-effectiveness of medical interventions, particularly when an intervention increases length of life more than quality of life. In older populations, current methods overstate the cast-effectiveness of interventions which extend life compared to interventions which improve the quality of life.
引用
收藏
页码:33 / 64
页数:32
相关论文
共 50 条
  • [21] Future Costs in Cost-Effectiveness Analyses: Past, Present, Future
    Linda M. de Vries
    Pieter H. M. van Baal
    Werner B. F. Brouwer
    PharmacoEconomics, 2019, 37 : 119 - 130
  • [22] Future Costs in Cost-Effectiveness Analyses: Past, Present, Future
    de Vries, Linda M.
    van Baal, Pieter H. M.
    Brouwer, Werner B. F.
    PHARMACOECONOMICS, 2019, 37 (02) : 119 - 130
  • [23] Cost-effectiveness - Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging measures: A comparison of five European countries
    Voelkel, Lukas
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2023, 28 (06): : 265 - 266
  • [24] Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis
    Hoyle, Martin
    PHARMACOECONOMICS, 2011, 29 (01) : 1 - 15
  • [25] Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis
    Martin Hoyle
    PharmacoEconomics, 2011, 29 : 1 - 15
  • [26] Future unrelated medical costs need to be considered in cost effectiveness analysis
    Pieter van Baal
    Alec Morton
    David Meltzer
    Werner Brouwer
    The European Journal of Health Economics, 2019, 20 : 1 - 5
  • [27] Future unrelated medical costs need to be considered in cost effectiveness analysis
    van Baal, Pieter
    Morton, Alec
    Meltzer, David
    Brouwer, Werner
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (01): : 1 - 5
  • [28] CATALOGUE OF AGE AND MEDICAL-CONDITION-SPECIFIC HEALTHCARE COSTS IN THE US TO INFORM FUTURE COSTS CALCULATIONS IN COST-EFFECTIVENESS ANALYSIS
    Jiao, Boshen
    Basu, Anirban
    MEDICAL DECISION MAKING, 2020, 40 (01) : E81 - E82
  • [29] Accounting for the placebo response in cost-effectiveness analysis
    McDonald, H. P.
    Rebeira, M.
    Wright, S.
    Jaszewski, B.
    VALUE IN HEALTH, 2008, 11 (03) : A172 - A172
  • [30] Accounting for Cured Patients in Cost-Effectiveness Analysis
    Othus, Megan
    Bansal, Aasthaa
    Koepl, Lisel
    Wagner, Samuel
    Ramsey, Scott
    VALUE IN HEALTH, 2017, 20 (04) : 705 - 709